scholarly journals Novel Redox-Responsive Polymeric Magnetosomes with Tunable Magnetic Resonance Property for In Vivo Drug Release Visualization and Dual-Modal Cancer Therapy

2018 ◽  
Vol 28 (33) ◽  
pp. 1802159 ◽  
Author(s):  
Zhongling Wang ◽  
Xiangdong Xue ◽  
Yixuan He ◽  
Ziwei Lu ◽  
Bei Jia ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Cancer Therapy ◽  
Drug Release ◽  
Resonance Property ◽  
Redox Responsive

scholarly journals Combining Dextran Conjugates with Stimuli-Responsive and Folate-Targeting Activity: A New Class of Multifunctional Nanoparticles for Cancer Therapy

Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1108
Author(s):  
Manuela Curcio ◽  
Alessandro Paolì ◽  
Giuseppe Cirillo ◽  
Sebastiano Di Pietro ◽  
Martina Forestiero ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Drug Release ◽  
Metastatic Cancer ◽  
Stimuli Responsive ◽  
Cancer Disease ◽  
New Class ◽  
Self Assembling ◽  
Redox Responsive ◽  
Potential Applicability ◽  
Mean Size

Nanoparticles with active-targeting and stimuli-responsive behavior are a promising class of engineered materials able to recognize the site of cancer disease, targeting the drug release and limiting side effects in the healthy organs. In this work, new dual pH/redox-responsive nanoparticles with affinity for folate receptors were prepared by the combination of two amphiphilic dextran (DEX) derivatives. DEXFA conjugate was obtained by covalent coupling of the polysaccharide with folic acid (FA), whereas DEXssPEGCOOH derived from a reductive amination step of DEX was followed by condensation with polyethylene glycol 600. After self-assembling, nanoparticles with a mean size of 50 nm, able to be destabilized in acidic pH and reducing media, were obtained. Doxorubicin was loaded during the self-assembling process, and the release experiments showed the ability of the proposed system to modulate the drug release in response to different pH and redox conditions. Finally, the viability and uptake experiments on healthy (MCF-10A) and metastatic cancer (MDA-MB-231) cells proved the potential applicability of the proposed system as a new drug vector in cancer therapy.

scholarly journals Novel concept of the smart NIR-light–controlled drug release of black phosphorus nanostructure for cancer therapy

2018 ◽  
Vol 115 (3) ◽  
pp. 501-506 ◽  
Author(s):  
Meng Qiu ◽  
Dou Wang ◽  
Weiyuan Liang ◽  
Liping Liu ◽  
Yin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Near Infrared ◽  
Black Phosphorus ◽  
Deep Penetration ◽  
Nir Light

A biodegradable drug delivery system (DDS) is one the most promising therapeutic strategies for cancer therapy. Here, we propose a unique concept of light activation of black phosphorus (BP) at hydrogel nanostructures for cancer therapy. A photosensitizer converts light into heat that softens and melts drug-loaded hydrogel-based nanostructures. Drug release rates can be accurately controlled by light intensity, exposure duration, BP concentration, and hydrogel composition. Owing to sufficiently deep penetration of near-infrared (NIR) light through tissues, our BP-based system shows high therapeutic efficacy for treatment of s.c. cancers. Importantly, our drug delivery system is completely harmless and degradable in vivo. Together, our work proposes a unique concept for precision cancer therapy by external light excitation to release cancer drugs. If these findings are successfully translated into the clinic, millions of patients with cancer will benefit from our work.

Plasmonic CuS nanodisk assembly based composite nanocapsules for NIR-laser-driven synergistic chemo-photothermal cancer therapy

2018 ◽  
Vol 6 (7) ◽  
pp. 1035-1043 ◽  
Author(s):  
Jian He ◽  
Lisha Ai ◽  
Xin Liu ◽  
Hao Huang ◽  
Yuebin Li ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Drug Release ◽  
Cancer Cells ◽  
Therapeutic Effects ◽  
Release Behavior ◽  
Sustained Drug Release ◽  
Drug Release Behavior ◽  
Nir Laser

The NIR-laser-driven plasmonic photothermal and sustained drug release behavior of CuS–PTX/SiO2 nanocapsules show great synergistic chemo-photothermal therapeutic effects on cancer cells in vitro and in vivo.

scholarly journals Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery

2020 ◽  
Vol 11 (12) ◽  
pp. 3268-3280 ◽  
Author(s):  
Gayathri R. Ediriweera ◽  
Joshua D. Simpson ◽  
Adrian V. Fuchs ◽  
Taracad K. Venkatachalam ◽  
Matthias Van De Walle ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Therapy ◽  
Drug Release ◽  
Standard Of Care ◽  
Release Profile ◽  
Specific Drug ◽  
Bioorthogonal Chemistry ◽  
Drug Release Profile ◽  
Therapeutic Delivery

There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile in vivo, as well as reducing side-effects for an increased standard of care.

scholarly journals Fluorinated EuII-based multimodal contrast agent for temperature- and redox-responsive magnetic resonance imaging

2017 ◽  
Vol 8 (12) ◽  
pp. 8345-8350 ◽  
Author(s):  
Lina A. Basal ◽  
Matthew D. Bailey ◽  
Jonathan Romero ◽  
Meser M. Ali ◽  
Lyazat Kurenbekova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agent ◽  
Contrast Enhancement ◽  
Resonance Imaging ◽  
Temperature Dependent ◽  
Redox Responsive

Mechanistically unique 19F-EuII/III complex reports redox in vivo using both 1H- and 19F-MRI and displays temperature-dependent contrast enhancement.

Real-Time In Vivo Quantitative Monitoring of Drug Release by Dual-Mode Magnetic Resonance and Upconverted Luminescence Imaging

2014 ◽  
Vol 53 (18) ◽  
pp. 4551-4555 ◽  
Author(s):  
Jianan Liu ◽  
Jiwen Bu ◽  
Wenbo Bu ◽  
Shengjian Zhang ◽  
Limin Pan ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Drug Release ◽  
Real Time ◽  
Dual Mode ◽  
Luminescence Imaging ◽  
Quantitative Monitoring

Fe3O4@carbon@zeolitic imidazolate framework-8 nanoparticles as multifunctional pH-responsive drug delivery vehicles for tumor therapy in vivo

2015 ◽  
Vol 3 (46) ◽  
pp. 9033-9042 ◽  
Author(s):  
Mengni He ◽  
Jiajia Zhou ◽  
Jian Chen ◽  
Fangcai Zheng ◽  
Dongdong Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Tumor Therapy ◽  
Controlled Drug Release ◽  
Ph Responsive ◽  
Zeolitic Imidazolate Framework ◽  
Drug Delivery Vehicles ◽  
Delivery Vehicles

Controlled drug release is a promising approach for cancer therapy due to its merits of reduced systemic toxicity and enhanced antitumor efficacy.

scholarly journals Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by in vivo magnetic resonance imaging.

1995 ◽  
Vol 39 (4) ◽  
pp. 839-845 ◽  
Author(s):  
R Weissleder ◽  
K Poss ◽  
R Wilkinson ◽  
C Zhou ◽  
A Bogdanov
Keyword(s):  
Magnetic Resonance Imaging ◽  
Polyethylene Glycol ◽  
Magnetic Resonance ◽  
Drug Release ◽  
Lethal Dose ◽  
Dimensional Structure ◽  
Therapeutic Drug ◽  
Resonance Imaging ◽  
Drug Concentrations

A biodegradable model hydrogel containing a covalently bound aminoglycoside in which drug release can be monitored by magnetic resonance imaging (MRI) in vivo was developed. The hydrogel consists of the bishydroxysuccinimide ester of polyethylene glycol disuccinate cross-linked albumin, to which gentamicin and Gd-diethylenetriaminepentaacetic acid are covalently attached in stochiometric quantities. MRI allowed us to depict the three-dimensional structure of implanted gels, to accurately calculate their volumes, and thus to calculate the concentration of hydrogel-bound gentamicin. The correlation coefficient for the concentration of released gentamicin and the hydrogel volume was 0.965. Free and hydrogel-released gentamicin conjugates had similar antibiotic efficacies when tested in microbiological agar diffusion assays. In vivo, hydrogel-released gentamicin had a longer half-life in plasma than unaltered gentamicin (5.6 versus 0.7 h), presumably because of residual bound polyethylene glycol residues. Hydrogel implants into rats resulted in a prolonged (7 to 10 days) release of gentamicin and a decreased 24-h mortality in mice infected with a lethal dose of Pseudomonas aeruginosa. The results indicate the feasibility of imaging and quantitating therapeutic drug concentrations in vivo by MRI.

Sign in / Sign up

Export Citation Format

Share Document